基线FDG PET异质性特征预测乳腺癌新辅助化疗后病理缓解
本综述检索PubMed数据库,纳入13项近5年发表的研究,评估基线18F-FDG PET原发肿瘤摄取异质性特征预测乳腺癌新辅助全身治疗病理缓解的潜力。13项研究中有8项提示FDG PET摄取异质性特征与病理缓解预测相关,但各研究采用的预测特征不一致,难以确立可重复的结论。
要点
- 13项研究中8项显示基线FDG PET摄取异质性特征与乳腺癌新辅助治疗后病理缓解预测相关。
- 各研究用于预测病理缓解的异质性特征不一致,难以确立可重复的结论。
- 缺乏共识可能反映纳入系列研究的异质性和数量较少。
核心结论
- 13项研究中8项提示基线FDG PET肿瘤摄取异质性特征与乳腺癌新辅助全身治疗病理缓解预测相关,但预测特征在各研究间不一致,难以确立可重复的结论;该主题的临床相关性支持进一步研究基线FDG PET的预测作用。
研究设计与样本
- 综述;在PubMed数据库进行文献检索,共纳入13项研究,均为近5年发表;收集每项入选研究的相关数据。
局限性
- 各研究用于预测新辅助全身治疗缓解的特征不一致,难以确立可重复的结论。
- 缺乏共识可能反映纳入系列研究的异质性和数量较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Complete pathological response to neoadjuvant systemic treatment (NAST) in some subtypes of breast cancer (BC) has been used as a surrogate of long-term outcome. The possibility of predicting BC pathological response to NAST based on the baseline 18F-Fluorodeoxyglucose positron emission tomography (FDG PET), without the need of an interim study, is a focus of recent discussion. This review summarises the characteristics and results of the available studies regarding the potential impact of heterogeneity features of the primary tumour burden on baseline FDG PET in predicting pathological response to NAST in BC patients. Literature search was conducted on PubMed database and relevant data from each selected study were collected. A total of 13 studies were eligible for inclusion, all of them published over the last 5 years. Eight out of 13 analysed studies indicated an association between FDG PET-based tumour uptake heterogeneity features and prediction of response to NAST. When features associated with predicting response to NAST were derived, these varied between studies. Therefore, definitive reproducible findings across series were difficult to establish. This lack of consensus may reflect the heterogeneity and low number of included series. The clinical relevance of this topic justifies further investigation about the predictive role of baseline FDG PET.
引用
- Oliveira, Oliveira, Vaz, et al. Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer. Br J Radiol. 2023. PMID: 36867773. doi:10.1259/bjr.20220655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。